IRUCAPARIB-AP6
|
|
|
- CAS号:
- 2410557-00-3
- 英文名:
- iRucaparib-AP6
- 英文别名:
- iRucaparib-AP6;1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[22-[4-(8-fluoro-3,4,5,6-tetrahydro-6-oxo-1H-pyrrolo[4,3,2-ef][2]benzazepin-2-yl)phenyl]-21-methyl-3,6,9,12,15,18-hexaoxa-21-azadocos-1-yl]amino]-
- 中文名:
- IRUCAPARIB-AP6
- 中文别名:
- IRUCAPARIB-AP6
- CBNumber:
- CB08037518
- 分子式:
- C46H55FN6O11
- 分子量:
- 886.96
- MOL File:
- 2410557-00-3.mol
|
|
|
IRUCAPARIB-AP6化学性质
-
沸点:
-
1057.6±65.0 °C(Predicted)
-
|
-
密度:
-
1.331±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 50 mg/mL (56.37 mM)
-
|
-
酸度系数(pKa):
-
10.74±0.40(Predicted)
-
|
IRUCAPARIB-AP6性质、用途与生产工艺
iRucaparib-AP6 是高效且特异的 PARP1 降解剂，基于 Rucaparib (PROTAC 的方法)。 iRucaparib-AP6 是一种 “非捕获性” PARP1 降解剂，可同时阻断 PARP1 的催化活性和支架作用。
iRucaparib-AP6 (0-10 μM; 24 hours) decreases PARP-1 level in a dose dependent manner, exhibits a half-maximal degrading concentration (DC
50
) of 82 nM (D
max
= 92%).
iRucaparib-AP6 (0-20 μM; 24 hours) induces degradation of PARP1 at low concentrations.
Cell Viability Assay
|
Cell Line:
|
Primary rat neonatal cardiomyocyte cells
|
|
Concentration:
|
0.001 μM; 0.01 μM; 0.1 μM; 1 μM; 10 μM
|
|
Incubation Time:
|
24 hours
|
|
Result:
|
Decreased PARP-1 level in primary rat neonatal cardiomyocyte cells.
|
Western Blot Analysis
|
Cell Line:
|
Primary rat neonatal cardiomyocyte cells
|
|
Concentration:
|
0.05 μM; 0.1 μM; 0.2 μM; 0.5 μM; 1 μM; 2 μM; 5 μM;10 μM; 20 μM
|
|
Incubation Time:
|
24 hours
|
|
Result:
|
Induced robust PARP1 degradation at concentrations as low as 50 nM.
|
IRUCAPARIB-AP6
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-130644 | IRUCAPARIB-AP6
iRucaparib-AP6 | 2410557-00-3 | 1mg | 5500元 |
| 2023/03/20 | HY-130644 | IRUCAPARIB-AP6
iRucaparib-AP6 | 2410557-00-3 | 5mg | 16500元 |
2410557-00-3, IRUCAPARIB-AP6 相关搜索:
- IRUCAPARIB-AP6
- 2410557-00-3
- 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[22-[4-(8-fluoro-3,4,5,6-tetrahydro-6-oxo-1H-pyrrolo[4,3,2-ef][2]benzazepin-2-yl)phenyl]-21-methyl-3,6,9,12,15,18-hexaoxa-21-azadocos-1-yl]amino]-
- iRucaparib-AP6